- Home
- ATEX vs PSNL Comparison
ATEX vs PSNL Comparison
Compare ATEX & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATEX
- PSNL
- Stock Information
- Founded
- ATEX 1997
- PSNL 2011
- Country
- ATEX United States
- PSNL United States
- Employees
- ATEX N/A
- PSNL N/A
- Industry
- ATEX Telecommunications Equipment
- PSNL Medical Specialities
- Sector
- ATEX Telecommunications
- PSNL Health Care
- Exchange
- ATEX Nasdaq
- PSNL Nasdaq
- Market Cap
- ATEX 528.1M
- PSNL 426.6M
- IPO Year
- ATEX N/A
- PSNL 2019
- Fundamental
- Price
- ATEX $27.52
- PSNL $6.42
- Analyst Decision
- ATEX Buy
- PSNL Strong Buy
- Analyst Count
- ATEX 2
- PSNL 5
- Target Price
- ATEX $64.00
- PSNL $8.00
- AVG Volume (30 Days)
- ATEX 124.7K
- PSNL 922.2K
- Earning Date
- ATEX 08-05-2025
- PSNL 08-06-2025
- Dividend Yield
- ATEX N/A
- PSNL N/A
- EPS Growth
- ATEX N/A
- PSNL N/A
- EPS
- ATEX N/A
- PSNL N/A
- Revenue
- ATEX $5,902,000.00
- PSNL $85,694,000.00
- Revenue This Year
- ATEX $49.39
- PSNL $0.45
- Revenue Next Year
- ATEX $2.84
- PSNL $25.75
- P/E Ratio
- ATEX N/A
- PSNL N/A
- Revenue Growth
- ATEX 66.77
- PSNL 15.57
- 52 Week Low
- ATEX $25.32
- PSNL $1.14
- 52 Week High
- ATEX $42.91
- PSNL $7.20
- Technical
- Relative Strength Index (RSI)
- ATEX 45.47
- PSNL 72.69
- Support Level
- ATEX $26.63
- PSNL $6.06
- Resistance Level
- ATEX $28.63
- PSNL $6.72
- Average True Range (ATR)
- ATEX 0.94
- PSNL 0.44
- MACD
- ATEX 0.21
- PSNL 0.10
- Stochastic Oscillator
- ATEX 63.20
- PSNL 85.65
About ATEX Anterix Inc.
Anterix Inc is a United States-based company engaged in delivering broadband needed to modernize infrastructure for energy, transportation, logistics, and other industries. The company offers Private LTE for utilities which help to automate processes, monitor environmental conditions, enable artificial intelligence, and drive productivity.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.